Showing results (281-290 of 292) with videos related to
Sort By:
Pageof 30
Plos Genetics|February 27, 2020
Metabolic and pathologic profiles of human LSS deficiency recapitulated in miceYoichi Wada, Atsuo Kikuchi, Akimune Kaga, et al.Toxicology in Vitro : an International Journal Published in Association with BIBRA|March 23, 2020
An international validation study of the IL-2 Luc assay for evaluating the potential immunotoxic effects of chemicals on T cells and a proposal for reference data for immunotoxic chemicalsYutaka Kimura, Rie Yasuno, Mika Watanabe, et al.American Journal of Medical Genetics. Part A|September 12, 2015
Somatic BRAF c.1799T>A p.V600E Mosaicism syndrome characterized by a linear syringocystadenoma papilliferum, anaplastic astrocytoma, and ocular abnormalitiesYuko Watanabe, Kosuke Shido, Tetsuya Niihori, et al.The Journal of Asthma : Official Journal of the Association for the Care of Asthma|March 18, 2014
Effects on asthma and induction of interleukin-8 caused by Asian dust particles collected in western JapanMasanari Watanabe, Jun Kurai, Katsuyuki Tomita, et al.Communications Medicine|January 5, 2025
Deep learning-based histopathological assessment of tubulo-interstitial injury in chronic kidney diseasesNonoka Suzuki, Kaname Kojima, Silvia Malvica, et al.Allergology International : Official Journal of the Japanese Society of Allergology|December 28, 2024
Efficacy of corneal squamous cell carcinoma antigen-1 in early infancy in predicting atopic dermatitis and food allergy: A prospective studyMaki Ozawa, Chika Katagiri, Chieko Okamura, et al.Frontiers in Medicine|May 14, 2019
Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced MelanomaTaku Fujimura, Yota Sato, Kayo Tanita, et al.Oncotarget|April 13, 2018
Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot studyTaku Fujimura, Yota Sato, Kayo Tanita, et al.Frontiers in Oncology|December 5, 2018
Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous MelanomaTaku Fujimura, Yota Sato, Kayo Tanita, et al.Journal of the American Academy of Dermatology|March 19, 2009
A randomized double-blind trial of intravenous immunoglobulin for pemphigusMasayuki Amagai, Shigaku Ikeda, Hiroshi Shimizu, et al.Pageof 30